Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate‐to‐severe plaque psoriasis and non‐pustular palmoplantar involvement: results from three phase 3 trials (<scp>UNCOVER</scp>‐1, <scp>UNCOVER</scp>‐2 and <scp>UNCOVER</scp>‐3)
Alan Menter(Baylor Medical Center at Garland), Kristian Reich(Dermatologikum Hamburg), Dante Amato(Autonomous University of Tlaxcala), Richard G. Langley(Dalhousie University), David Shrom(Eli Lilly (United States)), Joseph F. Merola(Southwestern Medical Center), Yusuke Okubo(Tokyo Medical University), Richard B. Warren(Manchester Academic Health Science Centre), Ellen B. Dennehy(Purdue University West Lafayette), Lisa Kerr(Eli Lilly (United States))
Cited by 74
Related Papers
Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathways
|Nature Genetics|2009|1.4k
The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation
|Psychological Medicine|2004|989
Effectiveness of Adjunctive Antidepressant Treatment for Bipolar Depression
|New England Journal of Medicine|2007|925
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics
|Journal of the American Academy of Dermatology|2019|917